The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates: Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan

PharmacoEconomics

Volumn 34, Issue 10, 2016, Pages 1005-1014

  Fukuda, Haruhisa ^a   Ikeda, Shunya ^b   Shiroiwa, Takeru ^c   Fukuda, Takashi ^c  

^a KYUSHU UNIVERSITY   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; DIABETIC NEPHROPATHY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEMODIALYSIS; HUMAN; ISCHEMIC HEART DISEASE; JAPAN; JAPANESE (PEOPLE); LIMB DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT IDENTIFICATION; PRIORITY JOURNAL; AGED; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; ECONOMICS; FACTUAL DATABASE; REGRESSION ANALYSIS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

ADULT; AGED; DATABASES, FACTUAL; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; JAPAN; MALE; MIDDLE AGED; MODELS, STATISTICAL; REGRESSION ANALYSIS; TIME FACTORS;

EID: 84961655039     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-016-0402-3     Document Type: Article

References (26)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033–46.
2. American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care. 2008;31:596–615.
3. Rice DP. Cost-of-illness studies: fact or fiction? Lancet. 1994;344:1519–20.
4. Ettaro L, Songer TJ, Zhang P, Engelgau MM. Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics. 2004;22:149–64.
5. Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015;33:811–31.
6. Ng CS, Lee JY, Toh MP, Ko Y. Cost-of-illness studies of diabetes mellitus: a systematic review. Diabetes Res Clin Pract. 2014;105:151–63.
7. Ringborg A, Yin DD, Martinell M, Stålhammar J, Lindgren P. The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden. Eur J Cardiovasc Prev Rehabil. 2009;16:576–82.
8. Clarke P, Leal J, Kelman C, Smith M, Colagiuri S. Estimating the cost of complications of diabetes in Australia using administrative health-care data. Value Health. 2008;11:199–206.
9. Oglesby AK, Secnik K, Barron J, Al-Zakwani I, Lage MJ. The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Eff Resour Alloc. 2006;4:1.
10. Okamoto E. Declining accuracy in disease classification on health insurance claims: should we reconsider classification by principal diagnosis? J Epidemiol. 2010;20:166–75.
11. Tanihara S, Okamoto E, Une H. A statistical analysis of ‘rule-out’ diagnoses in outpatient health insurance claims in Japan. J Eval Clin Pract. 2011;17:1070–4.
12. American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36:S11–66.
13. Kitazato H, Ikeda S, Izumi K, et al. A method to investigate medical expenditure in Japan in relationship of stage progression of type 2 diabetes mellitus complications and macroangiopathy. Obesity Diabetes. 2010;9:S48–64 [in Japanese].
14. Honeycutt AA, Segel JE, Hoerger TJ, et al. Comparing cost-of-illness estimates from alternative approaches: an application to diabetes. Health Serv Res. 2009;44:303–20.
15. Shrestha SS, Zhang P, Albright A, Finkelstein EA. Medical expenditures associated with diabetes among privately insured U.S. youth in 2007. Diabetes Care. 2011;34:1097–101.
16. Trogdon JG, Hylands T. Nationally representative medical costs of diabetes by time since diagnosis. Diabetes Care. 2008;31:2307–11.
17. Tunceli O, Wade R, Gu T, Bouchard JR, Aagren M, Luo W. Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods. Curr Med Res Opin. 2010;26:1827–34.
18. Pagano E, Bo S, Petrinco M, Rosato R, Merletti F, Gregori D. Factors affecting hospitalization costs in type 2 diabetic patients. J Diabetes Complicat. 2009;23:1–6.
19. Lee LJ, Yu AP, Cahill KE, et al. Direct and indirect costs among employees with diabetic retinopathy in the United States. Curr Med Res Opin. 2008;24:1549–59.
20. Fu AZ, Qiu Y, Radican L, Wells BJ. Health care and productivity costs associated with diabetic patients with macrovascular comorbid conditions. Diabetes Care. 2009;32:2187–92.
21. Durden ED, Alemayehu B, Bouchard JR, Chu BC, Aagren M. Direct health care costs of patients with type 2 diabetes within a privately insured employed population, 2000 and 2005. J Occup Environ Med. 2009;51:1460–5.
22. Currie CJ, Poole CD, Woehl A, et al. The financial costs of healthcare treatment for people with type 1 or type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy. Diabet Med. 2007;24:187–94.
23. Alva ML, Gray A, Mihaylova B, Leal J, Holman RR. The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med. 2015;32:459–66.
24. Clarke PM, Glasziou P, Patel A, et al. Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis. PLoS Med. 2010;7:e1000236.
25. Gerdtham UG, Clarke P, Hayes A, Gudbjornsdottir S. Estimating the cost of diabetes mellitus-related events from inpatient admissions in Sweden using administrative hospitalization data. Pharmacoeconomics. 2009;27:81–90.
26. Japan’s Health Service Bureau. National Health and Nutrition Survey 2007. http://www.mhlw.go.jp/bunya/kenkou/eiyou09/dl/01-kekka.pdf. Accessed 25 Jan 2016.